Here are relevant reports on : inflammatory-disease-therapeutics-market
-
Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease Area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) & Region - Global Forecast to 2028
The global antibody therapeutics market, valued at US$217.6 billion in 2022, stood at US$247.3 billion in 2023 and is projected to advance at a resilient CAGR of 14.1% from 2023 to 2028, culminating in a forecasted valuation of US$479.0 billion by the end of the period. Growth in the antibody therapeutics market is mainly driven by factors such as growing advancements in antibody engineering for development of novel therapeutics, growing R&D activities among others
- Published: December 2023
- Price: $ 4950
- TOC Available:
-
Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
The global monoclonal antibody therapeutics market, valued at US$222.6 billion in 2023, stood at US$252.6 billion in 2024 and is projected to advance at a resilient CAGR of 14.5% from 2024 to 2029, culminating in a forecasted valuation of US$497.5 billion by the end of the period. Driving factors of the market, including clinical trials, encompass increasing prevalence of complex diseases, advancements in biotechnology facilitating targeted treatments, regulatory support expediting approval processes, and robust investments in research and development.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
Rotator Cuff Injury Treatment Market by Modality (Surgical (Arthroscopy, Shoulder Replacement, Tendon Repair), Physiotherapy (Braces, Cold Compression), Drug Therapeutics (Anti-inflammatory Drugs, Injections), Orthobiologics) - Global Forecast to 2026
The global rotator cuff injury treatment market growth is primed to transition from $989.3 million in 2021 to $1,244.2 million by 2026, showcasing a strong CAGR of 4.7%. The key factors fueling the growth of this market include an increase in sports-related shoulder injuries, technological advancements in arthroscopic surgical devices, increase in aging population with osteoarthritis, strong focus of players towards launch of highly advanced arthroscopic treatment devices.
- Published: April 2022
- Price: $ 4950
- TOC Available:
-
C – Reactive Protein Testing Market by Assay Type (ELISA, Turbidimetric, Immunoturbidimetric), Application (Cardiovascular, Inflammatory Disease, Rheumatoid Arthritis, Cancer), End User (Hospitals, Clinics, Diagnostics Labs) - Global Forecast to 2023
The Global C-Reactive Protein Testing market is expected to reach USD 1.75 billion by 2023 from USD 1.62 billion in 2018, growing at a CAGR of 1.5 % from 2018 to 2023. Growing occurrences of Non Communicable Diseases (NCDs) such as Cardiovascular Diseases, Diabetes and other inflammatory diseases are the major drivers for this market. Point of Care technology for CRP testing is also being used for diagnostic purposes.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Autoimmunity Diagnostics Market by Product (Consumables, Instruments), Test Type (Routine, Autoantibody, Inflammatory, Urinalysis Tests), Disease (RA, SLE, MS, IBD), End User (Clinical Laboratories, Hospitals & Clinics) - Global Forecast to 2031
The global autoimmunity diagnostics market, valued at US$5.26 billion in 2024, stood at US$5.57 billion in 2025 and is projected to advance at a resilient CAGR of 8.3% from 2025 to 2031, culminating in a forecasted valuation of US$8.98 billion by the end of the period. The autoimmunity diagnostics market is consistently growing, fueled by several key factors. These include the rising prevalence of autoimmune disease, growing awareness about early and accurate diagnosis, increasing research activities, and rapid advancements in diagnostic technologies.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers) - Global Forecasts to 2024
The Lymphedema Diagnostics Market is expected to grow from USD 24 million in 2019 to USD 35 million by 2024, at a CAGR of 7.4% during the forecast period. The major players operating in the lymphedema diagnostics market are GE Healthcare (US), Philips (Netherlands), and Siemens Healthineers (Germany). Other prominent players in this market include Canon, Inc. (Japan), Shimadzu Corporation (Japan), Stryker Corporation (US), Fluoptics (France), United Imaging Healthcare Co., Ltd. (China), Hitachi, Ltd. (Japan), Esaote, SpA (Italy), Neusoft Corporation (China), Mindray Medical International, Ltd. (China), Mitaka USA, Inc. (US), Curadel, LLC (US), and ImpediMed Ltd. (Australia).
- Published: October 2019
- Price: $ 4950
- TOC Available:
-
Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2031
The human microbiome drugs market, valued at US$0.09 billion in 2024, stood at US$0.35 billion in 2025 and is projected to advance at a resilient CAGR of 35.2% from 2025 to 2031, culminating in a forecasted valuation of US$2.13 billion by the end of the period. The human microbiome drugs market is growing, driven by the increasing clinical success of live biotherapeutic products, rising prevalence of chronic and recurrent diseases, and expanding therapeutic applications beyond gastrointestinal disorders into metabolic, immune, and neurological conditions.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region - Global Forecast to 2030
The global oligonucleotide therapeutics market, valued at US$5.92 billion in 2024, stood at US$7.19 billion in 2025 and is projected to advance at a resilient CAGR of 19.7% from 2025 to 2030, culminating in a forecasted valuation of US$17.70 billion by the end of the period. The market is growing as more RNA-targeting therapies gain broader clinical acceptance. This increase is mainly driven by siRNAs and antisense candidates, supported by advances in delivery technologies like GalNAc conjugates and lipid nanoparticles.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) & Region - Global Forecast to 2028
The global RNA therapeutics market, valued at US$32.2 billion in 2022, stood at US$13.7 billion in 2023 and is projected to advance at a resilient CAGR of 5.6% from 2023 to 2028, culminating in a forecasted valuation of US$18.0 billion by the end of the period. Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines.
- Published: September 2023
- Price: $ 4950
- TOC Available:
-
Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032
The global exosome diagnostics and therapeutics market, valued at US$33 million in 2023, stood at US$59 million in 2024 and is projected to advance at a resilient CAGR of 81.2% from 2024 to 2032, culminating in a forecasted valuation of US$6,848 million by the end of the period. The growth of this market is driven by factors such as the increasing collaborations & commercialization initiatives, emerging potential of exosome-based liquid biopsy, and growing outsourcing of exosome manufacturing activities.
- Published: June 2024
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
